A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.

Panpan XieMorten T AbildlundTine A BaekdalXuemei HeYassine K Lyauk Usha Rani H Patted Zu Ning Aixin Shi

Published in: Diabetes, obesity & metabolism (2024)

At steady state, oral semaglutide exposure was dose dependent and close to dose proportionality in healthy Chinese subjects. This is consistent with previous clinical pharmacology results for oral semaglutide.

Keyphrases

double blind
placebo controlled
clinical trial
open label
phase iii
phase ii
study protocol
randomized controlled trial